Epix Launches Appeal For FDA Approval Of Vasovist
This article was originally published in The Pink Sheet Daily
Executive Summary
Epix is seeking an advisory committee review of its Vasovist imaging agent, which will be marketed by Schering AG if approved.
You may also be interested in...
Epix Finally Sells Vasovist and Flips Debt, But Will It Escape Bankruptcy?
Marrying off drugs inherited in Predix merger could help firm stay afloat.
Epix Finally Sells Vasovist and Flips Debt, But Will It Escape Bankruptcy?
Marrying off drugs inherited in Predix merger could help firm stay afloat.
FDA Denies Epix Appeal, Asks For New Vasovist Trials
Epix may raise the level of its appeal on the imaging agent to FDA’s Center for Drug Evaluation & Research.